SLRX Stock Overview
A clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Salarius Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.50 |
| 52 Week High | US$7.92 |
| 52 Week Low | US$1.35 |
| Beta | 0.93 |
| 11 Month Change | 42.85% |
| 3 Month Change | -11.63% |
| 1 Year Change | -48.54% |
| 33 Year Change | -97.94% |
| 5 Year Change | -99.67% |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Salarius pharmaceuticals announces 1-for-25 reverse stock split
Oct 14Salarius adds 12% after updates on clinical programs and financials
Sep 13Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers
Aug 22Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01
Aug 08Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement
Aug 02Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21
Jun 07Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow
May 27Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain
Feb 09
Salarius Pharmaceuticals receives second installment of $1.7M in payments
Jan 13Salarius Pharma raises $3.5M via warrant exercise
Dec 11Salarius Pharmaceuticals EPS in-line, beats on revenue
Nov 11Shareholder Returns
| SLRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 43.7% | 3.4% | -2.4% |
| 1Y | -48.5% | 17.1% | 17.5% |
Return vs Industry: SLRX underperformed the US Biotechs industry which returned 15.4% over the past year.
Return vs Market: SLRX underperformed the US Market which returned 17.2% over the past year.
Price Volatility
| SLRX volatility | |
|---|---|
| SLRX Average Weekly Movement | 31.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SLRX's share price has been volatile over the past 3 months.
Volatility Over Time: SLRX's weekly volatility has increased from 18% to 31% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 2 | David Arthur | www.salariuspharma.com |
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.
Salarius Pharmaceuticals, Inc. Fundamentals Summary
| SLRX fundamental statistics | |
|---|---|
| Market cap | US$1.28m |
| Earnings (TTM) | -US$8.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs SLRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.92m |
| Earnings | -US$8.92m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.94 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.2% |
How did SLRX perform over the long term?
See historical performance and comparison